The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration

• Published in: Thrombosis and haemostasis Vol. 99; no. 2; p. 409
• Main Authors: Jakubowski, Joseph A, Payne, Christopher D, Li, Ying G, Brandt, John T, Small, David S, Farid, Nagy A, Salazar, Daniel E, Winters, Kenneth J
• Format: Journal Article
• Language: English
• Published: Germany 01.02.2008
• Subjects: Adult; Aspirin - administration & dosage; Blood Coagulation Tests - instrumentation; Blood Coagulation Tests - methods; Blood Platelets - drug effects; Blood Platelets - metabolism; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring - instrumentation; Drug Monitoring - methods; Female; Humans; Male; Middle Aged; Piperazines - administration & dosage; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2 - blood; Receptors, Purinergic P2Y12; Reference Values; Reproducibility of Results; Thiophenes - administration & dosage; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives

Variability in response to antiplatelet agents has prompted the development of point-of-care (POC) technology. In this study, we compared the VerifyNow P2Y12 (VN-P2Y12) POC device with light transmission aggregometry (LTA) in subjects switched directly from clopidogrel to prasugrel. Healthy subjects...